trending Market Intelligence /marketintelligence/en/news-insights/trending/mPIW_swjNt0QT3-9VhWXVQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

GlycoMimetics' leukemia drug shows high remission rates in phase 1/2 trial

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

GlycoMimetics' leukemia drug shows high remission rates in phase 1/2 trial

GlycoMimetics Inc.'s drug candidate GMI-1271 showed high remission and low mortality rates in patients with acute myeloid leukemia in the phase 2 portion of its ongoing phase 1/2 clinical trial.

The trial showed that patients treated with GMI-1271 together with standard chemotherapy continue to achieve higher-than-expected remission rates based on historical controls, as well as lower-than-expected induction-related mortality rates. Treatment also continues to be well tolerated in 79 patients.

Data showed that among 54 relapsed/refractory acute myeloid leukemia patients, the overall response rate was 41% and the 60-day induction related mortality rate was 7%. The median overall survival time for phase 1 trial patients was 7.6 months.

Remissions were durable enough to allow 9 patients to receive stem cell transplants. More than half of patients who responded with a remission survived for at least a year after treatment.

Oral mucositis, or inflammation with mouth ulcers that is a sign of adverse effects of chemotherapy, was seen at low rates and severity with only one grade 3/4 event observed.

Further, among 25 newly diagnosed elderly patients, the overall response rate was 68%, with 73% in patients with de novo acute myeloid leukemia and 64% in patients with secondary acute myeloid leukemia.

The 60-day mortality rate was 8% and there were no cases of grade 3 or 4 mucositis.

For nine evaluable patients achieving complete remission or complete remission with incomplete marrow recovery, disease-free survival was 100% at six months after treatment.

GlycoMimetics submitted the data from the trial to the U.S. Food and Drug Administration. In May, the FDA granted GMI-1271 breakthrough therapy designation for the treatment of adult patients with relapsed/refractory acute myeloid leukemia.

The agency also granted fast-track status to the drug candidate. In addition, GMI-1271 has been granted orphan drug designation by the FDA and the European Commission.